Lantern Pharma to Showcase AI Co-Scientist Platform in Investor Briefing

Lantern Pharma (NASDAQ: LTRN) announced it will host an investor, analyst and shareholder briefing on April 9, 2026, at 8:30 a.m. Eastern, featuring a live demonstration of withZeta.ai, described as the first multi-agentic AI co-scientist for rare cancer drug discovery, development and clinical trial design. The webcast will highlight the platform’s capabilities, commercial architecture, competitive positioning and revenue strategy, alongside an overview of the rare cancer market opportunity and Lantern’s growth roadmap, with participation from CEO Panna Sharma and Chief Scientific Officer Kishor Bhatia.

The demonstration of withZeta.ai represents a significant development in oncology research, as the platform aims to address the high costs and lengthy timelines traditionally associated with cancer drug development. Lantern Pharma’s proprietary AI and machine learning platform, RADR(R), leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve real-world problems in oncology drug development. This approach has enabled the company to advance newly developed drug programs from initial AI insights to first-in-human clinical trials in 2–3 years and at approximately $1.0–2.5 million per program, a dramatic reduction compared to industry averages.

The company’s AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD. Lantern has established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of promising therapies for CNS and brain cancers. The investor briefing will provide insights into how the withZeta.ai platform integrates with Lantern’s existing RADR(R) system to further accelerate drug discovery and development processes.

This event matters because it showcases how artificial intelligence is transforming pharmaceutical research, particularly in the challenging area of rare cancers where traditional development models often prove economically unviable. The demonstration will illustrate how multi-agentic AI systems can function as co-scientists, potentially reducing the time and cost barriers that have limited rare cancer treatment development. For investors, the briefing offers critical insight into Lantern’s technological differentiation and commercial strategy in a market segment with significant unmet medical needs and substantial financial potential.

The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN. MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach target markets. For more information, please visit https://www.MissionIR.com. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.